Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
ГлавнаяРезультаты поиска
СтатьяИскать документыПерейти к записи. 2021; № 19: 134–146. DOI:10.21518/2079-701X-2021-19-134-146
Основные метаболические и токсические полинейропатии в клинической практике
Искать документыПерейти к записи[1]
Аффилированные организации
[1]Искать документыПерейти к записи
Аннотация
Полинейропатии – это заболевания периферической нервной системы с поражением моторных, сенсорных и/или вегетативных волокон, с которыми сталкиваются лечащие врачи практически всех специальностей амбулаторно и в клиниках. К настоящему времени выявлено более 100 различных причин развития полинейропатий. В группе вторичных полинейропатий наиболее часто приходится сталкиваться с метаболическими и токсическими полинейропатиями. Среди этих заболеваний лидирующее место занимают диабетические, алкогольные, уремические и лекарственно-индуцированные полинейропатии. Представлены основные формы диабетической полинейропатии. Основной клинической формой является дистальная симметричная полинейропатия. Клинические симптомы зависят от вида вовлеченных в патологический процесс волокон – тонких или толстых. Дана оценочная шкала в баллах для определения выраженности диабетической полинейропатии, что помогает в уточнении диагноза и прогноза заболевания. Следующей по частоте встречаемости среди метаболических полинейропатий является уремическая полинейропатия как наиболее частое осложнение у пациентов, страдающих хронической почечной недостаточностью. Описаны факторы риска развития уремической полинейропатии, клиническая картина, течение заболевания. В рамках токсических полинейропатий основное место уделено алкогольным полинейропатиям, вызванным химиотерапией и лекарственно-индуцированным. Для каждой из этих категорий описаны клинические формы, патофизиология развития. Для всех полинейропатий представлены основные диагностические аспекты. Показаны основные терапевтические подходы. Отдельное место отведено применению альфа-липоевой кислоты.
Ключевые слова
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Рубрики Mesh
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Литература

Kieseier B.C., Hartung H.P. Progress in Recognizing and Treating Polyneuropathy. Dtsch Arztebl Int. 2018;115(6):81–82. https://doi.org/10.3238/arztebl.2018.0081..
DOI: 10.3238/arztebl.2018.0081

Grantz M., Huan M.C. Unusual peripheral neuropathies. Part I: extrinsic causes. Semin Neurol. 2010;30(4):387–395. https://doi.org/10.1055/s-0030-1267282..
DOI: 10.1055/s-0030-1267282

Grantz M. Unusual peripheral neuropathies. Part II: intrinsic reactive causes. Semin Neurol. 2010;30(4):396–404. https://doi.org/10.1055/s-0030-1267283..
DOI: 10.1055/s-0030-1267283

Grantz M. Unusual peripheral neuropathies. Part III: intrinsic inherited causes. Semin Neurol. 2010;30(4):405–415. https://doi.org/10.1055/s-0030-1267284..
DOI: 10.1055/s-0030-1267284

Burns T.M., Mauermann M.L. The evaluation of polyneuropathies. Neurology. 2011;76(7 Suppl.):6–13. https://doi.org/10.1212/WNL.0b013e31820c3622..
DOI: 10.1212/WNL.0b013e31820c3622

England J.D., Gronseth G.S., Franklin G., Carter G.T., Kinsella L.J., Cohe J.A. et al. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidencebased review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology. 2009;72(2):177–184. https://doi.org/10.1212/01.wnl.0000336345.70511.0f..
DOI: 10.1212/01.wnl.0000336345.70511.0f

Hanewinckel R., van Oijen M., Ikram M.A., van Doorn P.A. The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol. 2016;31(1):5–20. https://doi.org/10.1007/s10654-015-0094-6..
DOI: 10.1007/s10654-015-0094-6

Bharucha N.E., Bharucha A.E., Bharucha E.P. Prevalence of peripheral neuropathy in the Parsi community of Bombay. Neurology. 1991;41(8):1315–1317. https://doi.org/10.1212/wnl.41.8.1315..
DOI: 10.1212/wnl.41.8.1315

Savettieri G., Rocca W.A., Salemi G., Meneghini F., Grigoletto F., Morgante L. et al. Prevalence of diabetic neuropathy with somatic symptoms: a door-to-door survey in two Sicilian municipalities. Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology. 1993;43(6):1115–1120. https://doi.org/10.1212/wnl.43.6.1115..
DOI: 10.1212/wnl.43.6.1115

Cruz M.E., Schoenberg B.S., Ruales J., Barberis P., Proano J., Bossano F. et al. Pilot study to detect neurologic disease in Ecuador among a population with a high prevalence of endemic goiter. Neuroepidemiology. 1985;4(2):108–116. https://doi.org/10.1159/000110221..
DOI: 10.1159/000110221

Osuntokun B.O., Adeuja A.O., Schoenberg B.S., Bademosi O., Nottidge V.A., Olumide A.O. et al. Neurological disorders in Nigerian Africans: a community-based study. Acta Neurol Scand. 1987;75(1):13–21. https://doi.org/10.1111/j.1600-0404.1987.tb07883.x..
DOI: 10.1111/j.1600-0404.1987.tb07883.x

Cruz Gutierrez-del-Olmo M., Schoenberg B.S., Portera-Sanchez A. Prevalence of neurological diseases in Madrid, Spain. Neuroepidemiology. 1989;8(1):43–47. https://doi.org/10.1159/000110164..
DOI: 10.1159/000110164

Longe A.C., Osuntokun B.O. Prevalence of neurological disorders in Udo, a rural community in southern Nigeria. Trop Geogr Med. 1989;41(1):36–40. Available at: https://pubmed.ncbi.nlm.nih.gov/2763344.https://pubmed.ncbi.nlm.nih.gov/2763344

Al Rajeh S., Bademosi O., Ismail H., Awada A., Dawodu A., Al-Freihi H. et al. A community survey of neurological disorders in Saudi Arabia: the Thugbah study. Neuroepidemiology. 1993;12(3):164–178. https://doi.org/10.1159/000110316..
DOI: 10.1159/000110316https://pubmed.ncbi.nlm.nih.gov/2763344

Kandil M.R., Darwish E.S., Khedr E.M., Sabry M.M., Abdulah M.A. A community-based epidemiological study of peripheral neuropathies in Assiut, Egypt. Neurol Res. 2012;34(10):960–966. https://doi.org/10.1179/1743132812Y.0000000099..
DOI: 10.1179/1743132812Y.0000000099

Kruja J., Beghi E., Zerbi D., Dobi D., Kuqo A., Zekja I. et al. High prevalence of major neurological disorders in two Albanian communities: results of a door-to-door survey. Neuroepidemiology. 2012;38(3):138–147. https://doi.org/10.1159/000336348..
DOI: 10.1159/000336348

Lor T.L., Boon K.Y., Cheo F.F., Lau S.C., Lee G.W., Ng B.H., Go K.J. The frequency of symptomatic sensory polyneuropathy in the elderly in an urban Malaysian community. Neurol Asia. 2009;14(2):109–113. Available at: https://neurology-asia.org/articles/20092_109.pdf.https://neurology-asia.org/articles/20092_109.pdf

Lor T.L., Boon K.Y., Cheo F.F., Lau S.C., Lee G.W., Ng B.H., Go K.J. The frequency of symptomatic sensory polyneuropathy in the elderly in an urban Malaysian community. Neurol Asia. 2009;14(2):109–113. Available at: https://neurology-asia.org/articles/20092_109.pdf.https://neurology-asia.org/articles/20092_109.pdf

Dewhurst F., Dewhurst M.J., Gray W.K., Aris E., Orega G., Howlett W. et al. The prevalence of neurological disorders in older people in Tanzania. Acta Neurol Scand. 2013;127(3):198–207. https://doi.org/10.1111/j.1600-0404.2012.01709.x..
DOI: 10.1111/j.1600-0404.2012.01709.x

Rothman K.J., Greenland S. Causation and causal inference in epidemiology. Am J Public Health. 2005;95(1 Suppl.):S144-S150. https://doi.org/10.2105/AJPH.2004.059204..
DOI: 10.2105/AJPH.2004.059204

McNeely M., Boyko E., Ahroni J., Stensel V.L., Reiber G.E., Smith D.G., Pecoraro R.F. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. How great are the risks? Diabetes Care. 1995;18(2):216–219. https://doi.org/10.2337/diacare.18.2.216..
DOI: 10.2337/diacare.18.2.216

Russell J.W., Zilliox L.A. Diabetic neuropathies. Continuum (Minneap Minn). 2014;20(5):1226–1240. https://doi.org/10.1212/01.CON.0000455884.29545.d2..
DOI: 10.1212/01.CON.0000455884.29545.d2

Boulton A.J., Knight G., Drury J., Ward J.D. The prevalence of symptomatic, diabetic neuropathy in an insulin-treated population. Diabetes Care. 1985;8(2):125–128. https://doi.org/10.2337/diacare.8.2.125..
DOI: 10.2337/diacare.8.2.125

Dyck P.J., Kratz K.M., Karnes J.L., Litchy W.J., Klein R., Pach J.M. et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43(4):817–824. https://doi.org/10.1212/wnl.43.4.817..
DOI: 10.1212/wnl.43.4.817

Franklin G.M., Kahn L.B., Baxter J., Marshall J.A., Hamman R.F. Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study. Amer J Epid. 1990;131(4):633–643. https://doi.org/10.1093/oxfordjournals.aje.a115547..
DOI: 10.1093/oxfordjournals.aje.a115547

Maser R.E., Steenkiste A.R., Dorman J.S., Nielsen V., Bass E., Manjoo Q. et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1989;38(11):1456–1461. https://doi.org/10.2337/diab.38.11.1456..
DOI: 10.2337/diab.38.11.1456

Partanen J., Niskanen L., Lehtinen J., Mervaala E., Siitonen O., Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulindependent diabetes mellitus. N Engl J Med. 1995;333(2):89–94. https://doi.org/10.1056/NEJM199507133330203..
DOI: 10.1056/NEJM199507133330203

Singleton J.R., Smith A.G., Bromberg M.B. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care. 2001;24(8):1448–1453. https://doi.org/10.2337/diacare.24.8.1448..
DOI: 10.2337/diacare.24.8.1448

Feldman E.L., Callaghan B.C., Pop-Busui R., Zochodne D.W., Wright D.E., Bennett D.L. et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5(1):42. https://doi.org/10.1038/s41572-019-0097-9..
DOI: 10.1038/s41572-019-0097-9

Divisova S., Vlckova E., Hnojcikova M., Skorna M., Nemec M., Dubovy P. et al. Prediabetes/early diabetes-associated neuropathy predominantly involves sensory small fibres. J Peripher Nerv Syst. 2012;17(3):341–350. https://doi.org/10.1111/j.1529-8027.2012.00420.x..
DOI: 10.1111/j.1529-8027.2012.00420.x

Abbott C.A., Malik R.A., van Ross E.R., Kulkarni J., Boulton A.J. Prevalence and characteristics of painful diabetic neuropathy in a large communitybased diabetic population in the U.K. Diabetes Care. 2011;34(10):2220–2224. https://doi.org/10.2337/dc11-1108..
DOI: 10.2337/dc11-1108

Malik R.A. Can diabetic neuropathy be prevented by angiotensinconverting enzyme inhibitors? Ann Med. 2000;32(1):1–5. https://doi.org/10.3109/07853890008995903..
DOI: 10.3109/07853890008995903

Tesfaye S., Stevens L., Stephenson J., Fuller J.H., Plater M., IonescuTirgoviste C. et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM complications study. Diabetologia. 1996;39(11):1377–1384. https://doi.org/10.1007/s001250050586..
DOI: 10.1007/s001250050586

Ropper A.H., Samuels M.A. (eds.). Adams and Victor’s Principles of Neurology. 9th ed. New York: McGraw-Hill; 2009. Available at: https://pdfdrive.com/adams-and-victors-principles-of-neurology-d175302779.html.https://pdfdrive.com/adams-and-victors-principles-of-neurology-d175302779.html

Ropper A.H., Samuels M.A. (eds.). Adams and Victor’s Principles of Neurology. 9th ed. New York: McGraw-Hill; 2009. Available at: https://pdfdrive.com/adams-and-victors-principles-of-neurology-d175302779.html.https://pdfdrive.com/adams-and-victors-principles-ofneurology-d175302779.html

Pop-Busui R., Boulton A.J.M., Feldman E.L., Bril V., Freeman R., Malik R.A. et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154. https://doi.org/10.2337/dc16-2042..
DOI: 10.2337/dc16-2042

Sinnreich M., Taylor B.V., Dyck P.J. Diabetic neuropathies. Classification, clinical features, and pathophysiological basis. Neurologist. 2005;11(2):63–79. https://doi.org/10.1097/01.nrl.0000156314.24508.ed..
DOI: 10.1097/01.nrl.0000156314.24508.ed

Пизова Н.В. Некоторые клинические проявления поражения нервной системы при сахарном диабете. Медицинский cовет. 2018;(9):104–111. https://doi.org/10.21518/2079-701X-2018-9-104-111..
DOI: 10.21518/2079-701X-2018-9-104-111

Dyck P.J., Albers J.W., Andersen H., Arezzo J.C., Biessels G.-J., Bril V. et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011;27(7):620–628. https://doi.org/10.1002/dmrr.1226..
DOI: 10.1002/dmrr.1226

Weisman A., Bril V., Ngo M., Lovblom L.E., Halpern E.M., Orszag A., Perkins B.A. Identification and prediction of diabetic sensorimotor polyneuropathy using individual and simple combinations of nerve conduction study parameters. PLoS ONE. 2013;8(3):e58783. https://doi.org/10.1371/journal.pone.0058783..
DOI: 10.1371/journal.pone.0058783

Perkins B.A., Orszag A., Ngo M., Ng E., New P.V., Bril V. Prediction of incident diabetic neuropathy using the monofilament examination: a 4-year prospective study. Diabetes Care. 2010;33(7):1549–1554. https://doi.org/10.2337/dc09-1835..
DOI: 10.2337/dc09-1835

Boulton A.J., Armstrong D.G., Albert S.F., Frykberg R.G., Hellman R., Kirkman M.S. et al. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care. 2008;31(8):1679–1685. https://doi.org/10.2337/dc08-9021..
DOI: 10.2337/dc08-9021

Kanji J.N., Anglin R.E., Hunt D.L., Panju A. Does this patient with diabetes have large-fiber peripheral neuropathy? JAMA. 2010;303(15):1526–1532. https://doi.org/10.1001/jama.2010.428..
DOI: 10.1001/jama.2010.428

Bouhassira D., Attal N., Alchaar H., Boureau F., Brochet B., Bruxelle J. et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114(1):29–36. https://doi.org/10.1016/j.pain.2004.12.010..
DOI: 10.1016/j.pain.2004.12.010

Krishnan A.V., Kiernan M.C. Neurological complications of chronic kidney disease. Nat Rev Neurol. 2009;5(10):542–551. https://doi.org/10.1038/nrneurol.2009.138..
DOI: 10.1038/nrneurol.2009.138

Rizzo M.A., Frediani F., Granata A., Ravasi B., Cusi D., Gallieni M. Neurological complications of hemodialysis: state of the art. J Nephrol. 2012;25(2):170–182. https://doi.org/10.5301/jn.5000087..
DOI: 10.5301/jn.5000087

Krishnan A.V., Kiernan M.C. Uremic neuropathy: clinical features and new pathophysiological insights. Muscle and Nerve. 2007;35(3):273–290. https://doi.org/10.1002/mus.20713..
DOI: 10.1002/mus.20713

Krishnan A.V., Pussell B.A., Kiernan M.C. Neuromuscular disease in the dialysis patient: an update for the nephrologist. Semin Dial. 2009;22(3):267–278. https://doi.org/10.1111/j.1525-139X.2008.00555.x..
DOI: 10.1111/j.1525-139X.2008.00555.x

Arnold R., Krishnan A. Neuropathy and other neurological problems in chronic kidney disease. In: Arici M. (ed.). Management of chronic kidney disease. Berlin: Springer; 2014, pp. 343–352. https://doi.org/10.1007/978-3-642-54637-2..
DOI: 10.1007/978-3-642-54637-2

Pop-Busui R., Roberts L., Pennathur S., Kretzler M., Brosius F.C., Feldman E.L. The management of diabetic neuropathy in CKD. Am J Kidney Dis. 2010;55(2):365–385. https://doi.org/10.1053/j.ajkd.2009.10.050..
DOI: 10.1053/j.ajkd.2009.10.050

Прилепская О.А., Кичерова О.А., Рейхерт Л.И. Клинические особенности уремической полинейропатии. Академический журнал Западной Сибири. 2016;12(4):66–68. Режим доступа: https://s2.siteapi.org/2272b53cc9c3a55/docs/jjiyn25tfbscokcc444ks8ssc8o0so.https://s2.siteapi.org/2272b53cc9c3a55/docs/jjiyn25tfbscokcc444ks8ssc8o0so

Прилепская О.А., Кичерова О.А., Рейхерт Л.И. Клинические особенности уремической полинейропатии. Академический журнал Западной Сибири. 2016;12(4):66–68. Режим доступа: https://s2.siteapi.org/2272b53cc9c3a55/docs/jjiyn25tfbscokcc444ks8ssc8o0so.https://s2.siteapi.org/2272b53cc9c3a55/docs/jjiyn25tfbscokcc444ks8ssc8o0so

Lakshman S.G., Ravikumar P., Kar G., Das D., Bhattacharjee K., Bhattacharjee P. A Comparative Study of Neurological Complications in Chronic Kidney Disease with Special Reference to its Stages and Haemodialysis Status. J Clin Diagn Res. 2016;10(12):OC01-OC04. https://doi.org/10.7860/JCDR/2016/22815.8947..
DOI: 10.7860/JCDR/2016/22815.8947

Babu M.M., Kiran M.R., Ravindra K., Srinivas V., Kandregula P., Vardhan R.V., Kumar N. Clinical manifestation and prevalence of peripheral neuropathy and nerve dysfunction in patients with chronic kidney disease. IJRMS. 2015;3(2):451–455. https://doi.org/10.5455/2320-6012.ijrms20150213..
DOI: 10.5455/2320-6012.ijrms20150213

Arnold R., Issar T., Krishnan A., Pussell B. Neurological complications in chronic kidney disease. JRSM Cardiovasc Dis. 2016;5. https://doi.org/10.1177/2048004016677687..
DOI: 10.1177/2048004016677687

Arnold R., Pussell B.A., Howells J, Grinius V., Kiernan M.C., Lin C., Krishnan A.V. Evidence for a causal relationship between hyperkalaemia and axonal dysfunction in end-stage kidney disease. Clin Neurophysiol. 2014;125(1):179–185. https://doi.org/10.1016/j.clinph.2013.06.022..
DOI: 10.1016/j.clinph.2013.06.022

McIntosh C. Alcohol and the nervous system. J Neurol Neurosurg Psychiatry. 2004;75:iii16-iii21. https://doi.org/10.1136/jnnp.2004.045708..
DOI: 10.1136/jnnp.2004.045708

Ravaglia S., Marchioni E., Costa A., Maurelli M., Moglia A. Erectile dysfunction as a sentinel symptom of cardiovascular autonomic neuropathy in heavy drinkers. J Peripher Nerv Syst. 2004;9(4):209–214. https://doi.org/10.1111/j.1085-9489.2004.09403.x..
DOI: 10.1111/j.1085-9489.2004.09403.x

Koike H., Iijima M., Sugiura M., Mori K., Hattori N., Ito H. et al. Alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy. Ann Neurol. 2003;54(1):19–29. https://doi.org/10.1002/ana.10550..
DOI: 10.1002/ana.10550

Julian T., Glascow N., Syeed R., Zis P. Alcohol-related peripheral neuropathy: a systematic review and meta-analysis. J Neurol. 2019;266(12):2907–2919. https://doi.org/10.1007/s00415-018-9123-1..
DOI: 10.1007/s00415-018-9123-1

Mygland A.M. P. Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol. 2001;8(2):157–165. https://doi.org/10.1046/j.1468-1331.2001.00187.x..
DOI: 10.1046/j.1468-1331.2001.00187.x

Lin K.P., Kwan S.Y., Chen S.Y., Chen S.S., Yeung K.B., Chia L.G., Wu Z.A. Generalized neuropathy in Taiwan: an etiologic survey. Neuroepidemiology. 1993;12:257–261. https://doi.org/10.1159/000110326..
DOI: 10.1159/000110326

Verghese J., Bieri P.L., Gellido C., Schaumburg H.H., Herskovitz S. Peripheral neuropathy in young-old and old-old patients. Muscle & Nerve. 2001;24(11):1476–1481. https://doi.org/10.1002/mus.1171..
DOI: 10.1002/mus.1171

Азимова Ю.Э., Ищенко К.А., Рачин А.П. Диагностика и лечение неврологических осложнений алкоголизма: «Новое вино в старых бокалах». Поликлиника. 2016;(1):50–56. Режим доступа: https://www.poliklin.ru/imagearticle/2016_1/50.pdf.https://www.poliklin.ru/imagearticle/2016_1/50.pdf

Азимова Ю.Э., Ищенко К.А., Рачин А.П. Диагностика и лечение неврологических осложнений алкоголизма: «Новое вино в старых бокалах». Поликлиника. 2016;(1):50–56. Режим доступа: https://www.poliklin.ru/imagearticle/2016_1/50.pdf.https://www.poliklin.ru/imagearticle/2016_1/50.pdf

Mathis S., Soulages A., Vallat J.M., Le Masson G. Epidemics and outbreaks of peripheral nervous system disorders: II. Toxic and nutritional causes. J Neurol. 2021;268(3):892–902. https://doi.org/10.1007/s00415-020-10216-8..
DOI: 10.1007/s00415-020-10216-8

Koike H., Sobue G. Alcoholic neuropathy. Curr Opin Neurol. 2006;19(5): 481–486. https://doi.org/10.1097/01.wco.0000245371.89941.eb..
DOI: 10.1097/01.wco.0000245371.89941.eb

Zambelis T., Karandreas N., Tzavellas E., Kokotis P., Liappas J. Large and small fiber neuropathy in chronic alcohol-dependent subjects. J Peripher Nerv Syst. 2005;10(4):375–381. https://doi.org/10.1111/j.1085-9489.2005.00050.x..
DOI: 10.1111/j.1085-9489.2005.00050.x

Palliyath S., Schwartz B.D. Peripheral nerve functions improve in chronic alcoholic patients on abstinence. J Stud Alcohol. 1993;54:684–686. https://doi.org/10.15288/jsa.1993.54.684..
DOI: 10.15288/jsa.1993.54.684

Monforte R., Estruch R., Valls-Solé J., Nicolás J., Villalta J., UrbanoMarquez A. Autonomic and peripheral neuropathies in patients with chronic alcoholism. A dose-related toxic effect of alcohol. Arch Neurol. 1995;52(1):45–51. https://doi.org/10.1001/archneur.1995.00540250049012..
DOI: 10.1001/archneur.1995.00540250049012

Vittadini G., Buonocore M., Colli G., Terzi M., Fonte R., Biscaldi G. Alcoholic polyneuropathy: a clinical and epidemiological study. Alcohol Alcohol. 2001;36(5):393–400. https://doi.org/10.1093/alcalc/36.5.393..
DOI: 10.1093/alcalc/36.5.393

Ammendola A., Gemini D., Iannaccone S., Argenzio F., Ciccone G., Ammendola E. et al. Gender and peripheral neuropathy in chronic alcoholism: a clinical-electroneurographic study. Alcohol and Alcoholism. 2000;35:368–371. https://doi.org/10.1093/alcalc/35.4.368..
DOI: 10.1093/alcalc/35.4.368

Agelink M.W., Malessa R., Weisser U., Lemmer W., Zeit T., Majewski T., Klieser E. Alcoholism, peripheral neuropathy (PNP) and cardiovascular autonomic neuropathy (CAN). J Neurol Sci. 1998;161(2):135–142. https://doi.org/10.1016/s0022-510x(98)00266-4..
DOI: 10.1016/s0022-510x(98)00266-4

Ammendola A., Tata M.R., Aurilio C., Ciccone G., Gemini D., Ammendola E. et al. Peripheral neuropathy in chronic alcoholism: a retrospective crosssectional study in 76 subjects. Alcohol and Alcoholism. 2001;36(3): 271–275. https://doi.org/10.1093/alcalc/36.3.271..
DOI: 10.1093/alcalc/36.3.271

Ng K., Lin C.S.-Y., Murray N.M. F., Burroughs A.K., Bostock H. Conduction and excitability properties of peripheral nerves in end-stage liver disease. Muscle & Nerve. 2007;35(6):730–738. https://doi.org/10.1002/mus.20765..
DOI: 10.1002/mus.20765

Estruch R., Nicolás J.M., Villegas E., Junqué A., Urbano-Márquez A. Relationship between ethanol-related diseases and nutritional status in chronically alcoholic men. Alcohol and Alcoholism. 1993;28(5):543–550. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8274178.https://www.ncbi.nlm.nih.gov/pubmed/8274178

Estruch R., Nicolás J.M., Villegas E., Junqué A., Urbano-Márquez A. Relationship between ethanol-related diseases and nutritional status in chronically alcoholic men. Alcohol and Alcoholism. 1993;28(5):543–550. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8274178.https://www.ncbi.nlm.nih.gov/pubmed/8274178

Michalak S., Michałowska-Wender G., Adamcewicz G., Wender M.B. Erythrocyte transketolase activity in patients with diabetic and alcoholic neuropathies. Folia Neuropathol. 2013;51(3):222–226. https://doi.org/10.5114/fn.2013.37706..
DOI: 10.5114/fn.2013.37706

Gimsing P., Melgaard B., Andersen K., Vilstrup H., Hippe E. Vitamin B-12 and Folate Function in Chronic Alcoholic Men with Peripheral Neuropathy and Encephalopathy. J Nutr. 1989;119(3):416–424. https://doi.org/10.1093/jn/119.3.416..
DOI: 10.1093/jn/119.3.416

Masaki T., Mochizuki H., Matsushita S., Yokoyama A., Kamakura K., Higuchi S. Association of aldehyde dehydrogenase-2 polymorphism with alcoholic polyneuropathy in humans. Neurosci Lett. 2004;363(3):288–290. https://doi.org/10.1016/j.neulet.2004.04.009..
DOI: 10.1016/j.neulet.2004.04.009

Hammoud N., Jimenez-Shahed J. Chronic Neurologic Effects of Alcohol. Clin Liver Dis. 2019;23(1):141–155. https://doi.org/10.1016/j.cld.2018.09.010..
DOI: 10.1016/j.cld.2018.09.010

Dervaux A., Laqueille X. Thiamine (vitamin B1) treatment in patients with alcohol dependence. Presse Med. 2017;46(2):165–171. https://doi.org/10.1016/j.lpm.2016.07.025..
DOI: 10.1016/j.lpm.2016.07.025

Пизова Н.В. Маски алкогольной полиневропатии. Неврология, нейропсихиатрия, психосоматика. 2020;12(2):114–118. https://doi.org/10.14412/2074-2711-2020-2-114-118..
DOI: 10.14412/2074-2711-2020-2-114-118

Koike H., Mori K., Misu K., Hattori N., Ito H., Hirayama M., Sobue G. Painful alcoholic polyneuropathy with predominant small-fiber loss and normal thiamine status. Neurology. 2001;56(12):1727–1732. https://doi.org/10.1212/wnl.56.12.1727..
DOI: 10.1212/wnl.56.12.1727

Левин О.С. Полиневропатии: клиническое руководство. М.: МИА; 2011. 469 с.

Курушина О.В., Барулин А.Е., Черноволенко Е.П. Алкогольная полинейропатия: пути диагностики и терапии. Медицинский совет. 2019;(1):58–63. https://doi.org/10.21518/2079-701X-2019-1-58-63..
DOI: 10.21518/2079-701X-2019-1-58-63

Briani C., Argyriou A.A., Izquierdo C., Velasco R., Campagnolo M., Alberti P. et al. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. J Peripher Nerv Syst. 2014;19: 299–306. https://doi.org/10.1111/jns.12097..
DOI: 10.1111/jns.12097

Staff N.P., Grisold A., Grisold W., Windebank A.J. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6): 772–781. https://doi.org/10.1002/ana.24951..
DOI: 10.1002/ana.24951

Geber C., Breimhorst M., Burbach B., Egenolf C., Baier B., Fechir M. et al. Pain in chemotherapy-induced neuropathy — more than neuropathic? Pain. 2013;154(12):2877–2887. https://doi.org/10.1016/j.pain.2013.08.028..
DOI: 10.1016/j.pain.2013.08.028

Kautio A.L., Haanpaa M., Kautiainen H., Kalso E., Saarto T. Burden of chemotherapy-induced neuropathy — a cross-sectional study. Support Care Cancer. 2011;19:1991–1996. https://doi.org/10.1007/s00520-010-1043-2..
DOI: 10.1007/s00520-010-1043-2

Hsu H.T., Wu L.M., Lin P.C., Juan C.H., Huang Y.Y., Chou P.L., Chen J.L. Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: a cross-sectional study. Medicine (Baltimore). 2020;99:e19029. https://doi.org/10.1097/MD.0000000000019029..
DOI: 10.1097/MD.0000000000019029

Seretny M., Currie G.L., Sena E.S., Ramnarine S., Grant R., MacLeod M. R. et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461–2470. https://doi.org/10.1016/j.pain.2014.09.020..
DOI: 10.1016/j.pain.2014.09.020

Sommer C., Geber C., Young P., Forst R., Birklein F., Schoser B. Polyneuropathies. Dtsch Arztebl Int. 2018;115(6):83–90. https://doi.org/10.3238/arztebl.2018.083..
DOI: 10.3238/arztebl.2018.083

Vilholm O.J., Christensen A.A., Zedan A.H., Itani M. Drug‐induced peripheral neuropathy. Basic Clin Pharmacol Toxicol. 2014;115(2):185–192. https://doi.org/10.1111/bcpt.12261..
DOI: 10.1111/bcpt.12261

Jones M.R., Urits I., Wolf J., Corrigan D., Colburn L., Peterson E. et al. Drug-Induced Peripheral Neuropathy: A Narrative Review. Curr Clin Pharmacol. 2020;15(1):38–48. https://doi.org/10.2174/1574884714666190121154813..
DOI: 10.2174/1574884714666190121154813

Green S., Holton A. Drug-induced peripheral neuropathy. Adverse Drug React. Bull. 2016;300(1):1159–1162. https://doi.org/10.1097/FAD.0000000000000020..
DOI: 10.1097/FAD.0000000000000020

Ma J., Kavelaars A., Dougherty P.M., Heijnen C.J. Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source. Cancer Wiley-Blackwell. 2018;124(11):2289–2298. https://doi.org/10.1002/cncr.31248..
DOI: 10.1002/cncr.31248

Wu C., Tcherny-Lessenot S., Dai W., Wang Y., Kechemir H., Gandhi S. et al. Assessing the risk for peripheral neuropathy in patients treated with dronedarone compared with that in other antiarrhythmics. Clin Ther. 2018;40(3):450–455. https://doi.org/10.1016/j.clinthera.2018.01.015..
DOI: 10.1016/j.clinthera.2018.01.015

Svendsen T. de K., Nørregaard H.P., García R.L. A., Andersen L., Hallas J., Hein S. S, Gaist D. Statins and polyneuropathy revisited: Case-control study in Denmark, 1999-2013. Br J Clin Pharmacol. 2017;83(9): 2087–2095. https://doi.org/10.1111/bcp.13298..
DOI: 10.1111/bcp.13298

Duffy L.F., Daum F., Fisher S.E., Selman J., Vishnubhakat S.M., Aiges H.W. et al. Peripheral neuropathy in Crohn’s di sease patients treated with metronidazole. Gastroenterology. 1985;88(3):681–684. https://doi.org/10.1016/0016-5085(85)90137-4..
DOI: 10.1016/0016-5085(85)90137-4

Toth C., Breithaupt K., Ge S., Duan Y., Terris J.M., Thiessen A. et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol. 2010;68(1):28–36. https://doi.org/10.1002/ana.22021..
DOI: 10.1002/ana.22021

Cossu G., Ceravolo R., Zibetti M., Arca R., Ricchi V., Paribello A. et al. Levodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibition. Park Relat Disord. 2016;27:81–84. https://doi.org/10.1016/j.parkreldis.2016.04.016..
DOI: 10.1016/j.parkreldis.2016.04.016

Merola A., Romagnolo A., Zibetti M., Bernardini A., Cocito D., Lopiano L. Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: A long-term prospective assessment. Eur J Neurol. 2016;23(3):501–509. https://doi.org/10.1111/ene.12846..
DOI: 10.1111/ene.12846

Ceravolo R., Cossu G., Bandettini di Poggio M., Santoro L., Barone P., Zibetti M. et al. Neuropathy and levodopa in Parkinson’s disease: Evidence from a multicenter study. Mov Disord. 2013;28(10):1391–1397. https://doi.org/10.1002/mds.25585..
DOI: 10.1002/mds.25585

Callaghan B.C., Kerber K.A., Lisabeth L.L., Morgenstern L.V., Longoria R., Rodgers A. et al. Role of neurologists and diagnostic tests on the management of distal symmetric polyneuropathy. JAMA Neurology. 2014;71(9):1143–1149. https://doi.org/10.1001/jamaneurol.2014.1279..
DOI: 10.1001/jamaneurol.2014.1279

Johannsen L., Smith T., Havsager A.M., Madsen C., Kjeldsen M.J., Dalsgaard N.J. et al. Evaluation of patients with symptoms suggestive of chronic polyneuropathy. J Clin Neur Dis. 2001;3(2):47–52. https://doi.org/10.1097/00131402-200112000-00001..
DOI: 10.1097/00131402-200112000-00001

Lubec D., Mullbacher W., Finsterer J., Mamoli B. Diagnostic work-up in peripheral neuropathy: an analysis of 171 cases. Post Med J. 1999;75(890):723–727. https://doi.org/10.1136/pgmj.75.890.723..
DOI: 10.1136/pgmj.75.890.723

Dyck P.J., Oviatt K.F., Lambert E.H. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Ann Neurol. 1981;10(3):222–226. https://doi.org/10.1002/ana.410100304..
DOI: 10.1002/ana.410100304

Notermans N.C., Wokke J.H., Franssen H., van der Graaf Y., Vermeulen M., van den Berg LH. et al. Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study of 75 patients. J Neurol Neurosurg Psychiatry. 1993;56(10):1066–1071. https://doi.org/10.1136/jnnp.56.10.1066..
DOI: 10.1136/jnnp.56.10.1066

Singer M.A., Vernino S.A., Wolfe G.I. Idiopathic neuropathy: new paradigms, new promise. J Peripher Nerv Syst. 2012;17(2 Suppl.):43–49. https://doi.org/10.1111/j.1529-8027.2012.00395.x..
DOI: 10.1111/j.1529-8027.2012.00395.x

Hughes R.A., Umapathi T., Gray I.A., Gregson N.A., Noori M., Pannala A.S. et al. A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain. 2004;127(8):1723–1730. https://doi.org/10.1093/brain/awh192..
DOI: 10.1093/brain/awh192

Ibrahim A., Jude E., Langton K., Martinez-De Jesus F.R., Harkless L.B., Gawish H. et al. International Diabetes Federation. Clinical Practice Recommendation on the Diabetic Foot: A guide for health care professionals: International Diabetes Federation. 2017. Available at: https://endocrinologie.usmf.md/sites/default/files/inline-files/IDF_DF_Foot_CPR_2017_Final[%]20[%]281[%]29.pdf.https://endocrinologie.usmf.md/sites/default/files/inline-files/IDF_DF_Foot_CPR_2017_Final[%]20[%]281[%]29.pdf

Ibrahim A., Jude E., Langton K., Martinez-De Jesus F.R., Harkless L.B., Gawish H. et al. International Diabetes Federation. Clinical Practice Recommendation on the Diabetic Foot: A guide for health care professionals: International Diabetes Federation. 2017. Available at: https://endocrinologie.usmf.md/sites/default/files/inline-files/IDF_DF_Foot_CPR_2017_Final[%]20[%]281[%]29.pdf.https://endocrinologie.usmf.md/sites/default/files/inline-files/IDF_DF_Foot_CPR_2017_Final[%]20[%]281[%]29.pdf

Reed L.J., DeBusk B. G., Gunsalus I.C., Hornberger C.S. Crystalline α-lipoic acid: A catalytic agent associated with pyruvate dehydrogenase. Science. 1951;114(2952):93–94. https://doi.org/10.1126/science.114.2952.93..
DOI: 10.1126/science.114.2952.93

Salehi B., Yılmaz B.Y., Antika G., Boyunegmez T.T., Fawzi M.M., Lobine D. et al. Insights on the Use of alpha-Lipoic Acid for Therapeutic Purposes. Biomolecules. 2019;9(8):356. https://doi.org/10.3390/biom9080356..
DOI: 10.3390/biom9080356

Singh U., Jialal I. Retracted: Alpha-lipoic acid supplementation and diabetes. Nutr Rev. 2008;66(11):646–657. https://doi.org/10.1111/j.1753-4887.2008.00118.x..
DOI: 10.1111/j.1753-4887.2008.00118.x

Maglione E., Marrese C., Migliaro E., Marcuccio F., Panico C., Salvati C. et al. Increasing bioavailability of (R)-alpha-lipoic acid to boost antioxidant activity in the treatment of neuropathic pain. Acta BioMedica Atenei Parm. 2015;86(3):226–233. Available at: https://pubmed.ncbi.nlm.nih.gov/26694149.https://pubmed.ncbi.nlm.nih.gov/26694149

Maglione E., Marrese C., Migliaro E., Marcuccio F., Panico C., Salvati C. et al. Increasing bioavailability of (R)-alpha-lipoic acid to boost antioxidant activity in the treatment of neuropathic pain. Acta BioMedica Atenei Parm. 2015;86(3):226–233. Available at: https://pubmed.ncbi.nlm.nih.gov/26694149.https://pubmed.ncbi.nlm.nih.gov/26694149

Packer L., Cadenas E. Lipoic acid: Energy metabolism and redox regulation of transcription and cell signaling. J Clin Biochem Nutr. 2010;48(1):26–32. https://doi.org/10.3164/jcbn.11-005FR..
DOI: 10.3164/jcbn.11-005FR

Konrad D., Somwar R., Sweeney G., Yaworsky K., Hayashi M., Ramlal T., Klip A. The antihyperglycemic drug alpha-lipoic acid stimulates glucose uptake via both GLUT4 translocation and GLUT4 activation: Potential role of p38 mitogen-activated protein kinase in GLUT4 activation. Diabetes. 2001;50(6):1464–1471. https://doi.org/10.2337/diabetes.50.6.1464..
DOI: 10.2337/diabetes.50.6.1464

Chen W.-L., Kang C.-H., Wang S.-G., Lee H.-M. α-Lipoic acid regulates lipid metabolism through induction of sirtuin 1 (SIRT1) and activation of AMP-activated protein kinase. Diabetologia. 2012;55:1824–1835. https://doi.org/10.1007/s00125-012-2530-4..
DOI: 10.1007/s00125-012-2530-4

Gorąca A., Huk-Kolega H., Piechota A., Kleniewska P., Ciejka E., Skibska B. Lipoic acid – biological activity and therapeutic potential. Pharmacol Rep. 2011;63(4):849–858. https://doi.org/10.1016/S1734-1140(11)70600-4..
DOI: 10.1016/S1734-1140(11)70600-4

Han D., Handelman G., Marcocci L., Sen C.K., Roy S., Kobuchi H. et al. Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization. Biofactors. 1997;6(3):321–338. https://doi.org/10.1002/biof.5520060303..
DOI: 10.1002/biof.5520060303

Shay K.P., Moreau R.F., Smith E.J., Smith A.R., Hagen T.M. Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009;1790(10):1149–1160. https://doi.org/10.1016/j.bbagen.2009.07.026..
DOI: 10.1016/j.bbagen.2009.07.026

Ou P., Tritschler H.J., Wolff S.P. Thioctic (lipoic) acid: A therapeutic metalchelating antioxidant? Biochem Pharmacol. 1995;50(1):123–126. https://doi.org/10.1016/0006-2952(95)00116-H..
DOI: 10.1016/0006-2952(95)00116-H

Stevens M.J., Obrosova I., Cao X., Van Huysen C., Greene D.A. Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes. 2000; 49(6):1006–1015. https://doi.org/10.2337/diabetes.49.6.1006..
DOI: 10.2337/diabetes.49.6.1006

van Dam P.S., van Asbeck B.S., Van Oirschot J.F., Biessels G.J., Hamers F.P., Marx J.J. Glutathione and alpha-lipoate in diabetic rats: nerve function, blood flow and oxidative state. Eur J Clin Invest. 2001;31(5):417–424. https://doi.org/10.1046/j.1365-2362.2001.00832.x..
DOI: 10.1046/j.1365-2362.2001.00832.x

Ford I., Cotter M.A., Cameron N.E., Greaves M. The effects of treatment with alpha-lipoic acid or evening primrose oil on vascular hemostatic and lipid risk factors, blood flow, and peripheral nerve conduction in the streptozotocin-diabetic rat. Metabolism. 2001;50(8):868–875. https://doi.org/10.1053/meta.2001.24914..
DOI: 10.1053/meta.2001.24914

Sun L., Chen Y., Wang X., Li X., Xue B., Qu L. et al. The protective effect of alpha lipoic acid on Schwann cells exposed to constant or intermittent high glucose. Biochem Pharmacol. 2012;84(7):961–973. https://doi.org/10.1016/j.bcp.2012.07.005..
DOI: 10.1016/j.bcp.2012.07.005

Heitzer T., Finckh B., Albers S., Krohn K., Kohlschütter A., Meinertz T. Benefficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med. 2001;31(1):53–61. https://doi.org/10.1016/s0891-5849(01)00551-2..
DOI: 10.1016/s0891-5849(01)00551-2

Castro M.C., Villagarcía H.G., Massa M.L., Francini F. Alpha-lipoic acid and its protective role in fructose induced endocrine-metabolic disturbances. Food Funct. 2019;10(1):16–25. https://doi.org/10.1039/C8FO01856A..
DOI: 10.1039/C8FO01856A

Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: A critical review. Treat Endocrino. 2004;3:173–179. https://doi.org/10.2165/00024677-200403030-00005..
DOI: 10.2165/00024677-200403030-00005

Henriksen E.J. Exercise training and the antioxidant alpha-lipoic acid in the treatment of insulin resistance and type 2 diabetes. Free Radic Boil Med. 2006;40(1):3–12. https://doi.org/10.1016/j.freeradbiomed.2005.04.002..
DOI: 10.1016/j.freeradbiomed.2005.04.002

Reljanovic M., Reichel G., Rett K., Lobisch M., Schuette K., Möller W. et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res. 1999;31(3):171–179. https://doi.org/10.1080/10715769900300721..
DOI: 10.1080/10715769900300721

Ziegler D., Hanefeld M., Ruhnau R.J., Hasche H., Lobisch M., Schütte K. et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alphalipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999;22(8):1296–1301. https://doi.org/10.2337/diacare.22.8.1296..
DOI: 10.2337/diacare.22.8.1296

Терещенко И.В. Берлитион – залог успеха в лечении полинейропатии. Поликлиника. 2014;(5):21–24. Режим доступа: https://www.poliklin.ru/imagearticle/201405(1)/21-24.pdf.https://www.poliklin.ru/imagearticle/201405(1)/21-24.pdf

Терещенко И.В. Берлитион – залог успеха в лечении полинейропатии. Поликлиника. 2014;(5):21–24. Режим доступа: https://www.poliklin.ru/imagearticle/201405(1)/21-24.pdf.https://www.poliklin.ru/imagearticle/201405(1)/21-24.pdf

Бойко А.Н., Камчатнов П.Р. Возможности применения берлитиона при диабетической полинейропатии. Справочник поликлинического врача. 2013;(10):42–45. Режим доступа: https://omnidoctor.ru/library/izdaniyadlya-vrachey/spravochnik-poliklinicheskogo-vracha/spv2013/spv2013_10/vozmozhnosti-primeneniya-berlitiona-pri-diabeticheskoypolineyropatii.https://omnidoctor.ru/library/izdaniyadlya-vrachey/spravochnik-poliklinicheskogo-vracha/spv2013/spv2013_10/vozmozhnosti-primeneniya-berlitiona-pri-diabeticheskoypolineyropatii

Бойко А.Н., Камчатнов П.Р. Возможности применения берлитиона при диабетической полинейропатии. Справочник поликлинического врача. 2013;(10):42–45. Режим доступа: https://omnidoctor.ru/library/izdaniyadlya-vrachey/spravochnik-poliklinicheskogo-vracha/spv2013/spv2013_10/vozmozhnosti-primeneniya-berlitiona-pri-diabeticheskoypolineyropatii.https://omnidoctor.ru/library/izdaniya-dlya-vrachey/spravochnik-poliklinicheskogo-vracha/spv2013/spv2013_10/vozmozhnosti-primeneniya-berlitiona-pri-diabeticheskoy-polineyropatii

Данилов А.Б., Пилипович А.А. Тиоктовая кислота: современная терапия диабетической полинейропатии. Эффективная фармакотерапия. 2017;(2):14–20. Режим доступа: https://umedp.ru/articles/tioktovaya_kislota_sovremennaya_terapiya_diabeticheskoy_polinevropatii.html?sphrase_id=74098.https://umedp.ru/articles/tioktovaya_kislota_sovremennaya_terapiya_diabeticheskoy_polinevropatii.html?sphrase_id=74098

Данилов А.Б., Пилипович А.А. Тиоктовая кислота: современная терапия диабетической полинейропатии. Эффективная фармакотерапия. 2017;(2):14–20. Режим доступа: https://umedp.ru/articles/tioktovaya_kislota_sovremennaya_terapiya_diabeticheskoy_polinevropatii.html?sphrase_id=74098.https://umedp.ru/articles/tioktovaya_kislota_sovremennaya_terapiya_diabeticheskoy_polinevropatii.html?sphrase_id=74098

Воробьева О.В. Клинический разбор пациента с коморбидными неврологическими осложнениями сахарного диабета в практике амбулаторного врача: взгляд невролога. Трудный пациент. 2018;16(11):35–39. https://doi.org/10.24411/2074-1995-2018-10028..
DOI: 10.24411/2074-1995-2018-10028

Дадашева М.Н., Горенков Р.В., Дадашева К.Н. Ранняя диагностика и современные аспекты лечения диабетической полинейропатии. Трудный пациент. 2020;18(4):6–9. https://doi.org/10.24411/2074-1995-2020-10022..
DOI: 10.24411/2074-1995-2020-10022

Ковражкина Е.А. Аксональные полинейропатии: патогенез и лечение. Журнал неврологии и психиатрии им. C.C. Корсакова. 2013;113(6):22–25. Режим доступа: https://mediasphera.ru/issues/zhurnal-nevrologii-ipsikhiatrii-im-s-s-korsakova/2013/6/downloads/ru/031997-7298201364.https://mediasphera.ru/issues/zhurnal-nevrologii-ipsikhiatrii-im-s-s-korsakova/2013/6/downloads/ru/031997-7298201364

Ковражкина Е.А. Аксональные полинейропатии: патогенез и лечение. Журнал неврологии и психиатрии им. C.C. Корсакова. 2013;113(6):22–25. Режим доступа: https://mediasphera.ru/issues/zhurnal-nevrologii-ipsikhiatrii-im-s-s-korsakova/2013/6/downloads/ru/031997-7298201364.https://mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-skorsakova/2013/6/downloads/ru/031997-7298201364

Храмилин В.Н., Чазова Т.Е. Опыт клинического применения Берлитиона при диабетической периферической полинейропатии. Сахарный диабет. 2001;4(4):46–51. https://doi.org/10.14341/DM2001446-51..
DOI: 10.14341/DM2001446-51

Зиновьева О.Е. Антиоксидантная терапия диабетической нейропатии. РМЖ. 2006;(9):647. Режим доступа: https://rmj.ru/articles/obshchie-stati/Antioksidantnaya_terapiya_diabeticheskoy_nevropatii.https://rmj.ru/articles/obshchie-stati/Antioksidantnaya_terapiya_diabeticheskoy_nevropatii

Зиновьева О.Е. Антиоксидантная терапия диабетической нейропатии. РМЖ. 2006;(9):647. Режим доступа: https://rmj.ru/articles/obshchie-stati/Antioksidantnaya_terapiya_diabeticheskoy_nevropatii.https://www.rmj.ru/articles/obshchie-stati/Antioksidantnaya_terapiya_diabeticheskoy_nevropatii

Collins M.P., Hadden R.D. The nonsystemic vasculitic neuropathies. Nat Rev Neurol. 2017;13:302–316. https://doi.org/10.1038/nrneurol.2017.42..
DOI: 10.1038/nrneurol.2017.42

Üçeyler N., Rogausch J.P., Toyka K.V., Sommer C. Differential expression of cytokines in painful and painless neuropathies. Neurology. 2007;69(1):42–49. https://doi.org/10.1212/01.wnl.0000265062.92340.a5..
DOI: 10.1212/01.wnl.0000265062.92340.a5

Finnerup N.B., Attal N., Haroutounian S., McNicol E., Baron R., Dworkin R. et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173. https://doi.org/10.1016/S1474-4422(14)70251-0..
DOI: 10.1016/S1474-4422(14)70251-0

Дополнительная информация
Язык текста: Русский
ISSN: 2079-701X
Унифицированный идентификатор ресурса для цитирования: //medj.rucml.ru/journal/4e432d4d4544534f5645542d41525449434c452d323032312d302d31392d302d3133342d313436/